For many years we have known that amyloid deposits in the brain cause Alzheimer’s, and the more deposits the worse the disease becomes. In 2011 scientists from ModGene LLC and Scripps Research Institute found that these deposits in the brain may come from the liver. This week our clinical text …

Working with a patient, a woman, 44 years of age, who has had type 1 diabetes 21 years. She had a day of high glucose levels. We worked together very hard all day correcting to bring it down. After being closer to her target range, not low by any means, she told me she just had some chocolate. I asked her why, after the day she had, did she choose chocolate.

In part 4 of this Exclusive Interview, Eran Bashan explains how diabetes educators and physicians provide patient support with the d-Nav solution.

In this week's Homerun Slides, we continue exploring the mechanisms of diabetes with a brief focus on immune modulation/inflammation, insulin resistance and environment.

Chronically elevated glucose and/or free fatty acids: type 2 diabetes is characterized by increased circulating nutrients including glucose and free fatty acids (FFA).The literature clearly shows that chronic exposure of beta cells to elevated glucose results in impaired beta-cell function, but the data regarding cellular toxicity in response to this nutrient are more mixed.

Over the past 4 months, we have had over 22 items looking at the cardiovascular effects of diabetes drugs. Some of the items were focused on the increased risk of cardiovascular events; others were focused on the benefits in patients to either prevent or help reduce cv events; and a third group …

A year after the FDA warning, a strong response to the question: are SGLT-2 inhibitors safe?

This is the fourth drug to treat diabetes that also can reduce the risk of heart disease.

Mrs. Wilson is an overweight 71-year-old African-American patient who has come to your clinic today for a new patient visit. She recently moved to the area to live with her daughter and is concerned about her diabetes care plan. She was diagnosed with type 2 diabetes 12 years ago at a wellness check through routine screening. In hindsight, she wonders if maybe she “went undiagnosed for a while” because she “didn’t get to the clinic very often and was having some problems with frequent urination at night” before she was screened. She currently takes metformin, glyburide, captopril, pravastatin, aspirin and has recently titrated to .6 U/kg/day insulin NPH as a nightly basal dose. Her current A1C goal is below 7.5% and she has been working hard to get to that level. However, for the first time in her life, she is finding herself to be nauseated and irritable in the morning, but always feels better after a little breakfast. She states she feels “pretty good for her age” although she occasionally has “a little chest tightness when walking more than 4 or 5 blocks.” Last time she remembered to check it a few days ago, her postprandial glucose was a little high at 214 mg/dL. Her office A1C is 8.6%. Based on her history, what would be an acceptable individualized A1C goal for this patient? A. A1C less than 6.5% B. A1C less than 7.0% C. A1C less than 8.0% D. A1C greater than 8.0% Are you right? Follow the link to find out!

A secondary analysis of the TECOS trial affirms sitagliptin does not increase heart failure risk for patients with type 2 diabetes.